Stability differences between condition 1 and other conditions across participants on the non-hemiparetic side (NHP) side. حسب Hyung Suk Yang (20442438)

الموضوعات:

Stability differences between condition 1 and other conditions across participants on the hemiparetic (HP) side. حسب Hyung Suk Yang (20442438)

الموضوعات:

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count. حسب Francesca Catto (21253435)

"…Additionally, the plots on the right side display the average plaque count across the cohorts. …"

Brain regions with significantly decreased activations for the Raven task are shown in blue. حسب Morteza Fattahi (15892028)

Transepithelial resistance of NHBE decreases significantly after PAA exposure. حسب Ellie S. Burns (21246537)

BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. حسب Luqiong Liu (11537092)

Side effect. حسب My Tra Thi Nguyen (22120541)

"…QoL also significantly improved, with CU-Q2oL scores dropping from 44.9 at baseline to 25.3 at week 8. …"

Inotodiol decreases clone formation in HCC cells. حسب Yushuang Xing (20636685)

"…Chemicals and chemotherapeutic agents have been experiencing problems such as side effects and drug resistance in the treatment of HCC, which cannot meet the needs of clinical treatment. …"

Inotodiol decreases clone formation in HCC cells. حسب Yushuang Xing (20636685)

BA attenuated the decrease in the integrity and increase in the permeability of the epithelial barrier injury induced by LPS in Caco2 cell monolayers. حسب Luqiong Liu (11537092)

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

الموضوعات:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. حسب Claire M. Douglas (21238238)

الموضوعات:

Participant demographic and clinical characteristics. حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... حسب Claire M. Douglas (21238238)

الموضوعات:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... حسب Claire M. Douglas (21238238)

الموضوعات:

Schematic representation of the study protocol. حسب Neng Pan (5262032)

الموضوعات:

Baseline characteristics. حسب Neng Pan (5262032)

الموضوعات:

Comparison within groups. حسب Neng Pan (5262032)

الموضوعات: